CN Patent

CN112057427B — 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法

Assigned to Beone Pharmaceutical Suzhou Co Ltd · Expires 2024-09-03 · 2y expired

What this patent protects

本发明提供了一种含有(S)‑7‑[4‑(1‑丙烯酰基哌啶)]‑2‑(4‑苯氧基苯基)4，5，6，7‑四氢吡唑并[1，5‑a]嘧啶‑3‑甲酰胺的口服固体片剂及其制备方法。本发明所述口服固体片剂具有良好的药物释放特性，且用药方便，释放迅速高效，对设备无特殊要求，制剂工艺简单，能够保证制剂稳定性，便于运输和储藏，适合规模化生产。

USPTO Abstract

本发明提供了一种含有(S)‑7‑[4‑(1‑丙烯酰基哌啶)]‑2‑(4‑苯氧基苯基)4，5，6，7‑四氢吡唑并[1，5‑a]嘧啶‑3‑甲酰胺的口服固体片剂及其制备方法。本发明所述口服固体片剂具有良好的药物释放特性，且用药方便，释放迅速高效，对设备无特殊要求，制剂工艺简单，能够保证制剂稳定性，便于运输和储藏，适合规模化生产。

Drugs covered by this patent

Patent Metadata

Patent number
CN112057427B
Jurisdiction
CN
Classification
—
Expires
2024-09-03
Drug substance claim
No
Drug product claim
No
Assignee
Beone Pharmaceutical Suzhou Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.